NCT07008508View on ClinicalTrials.gov

Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study

Active, not recruitingOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

May 31, 2032

Study Completion Date

May 31, 2032

Conditions

Breast Cancer

Interventions

DRUG

Cyclin-dependent Kinase 4/6 Inhibitor

Planned new line of Cyclin-dependent Kinase 4/6 Inhibitor

Trial Locations (1)

00168

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome

All Listed Sponsors

lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT07008508 - Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study | Biotech Hunter | Biotech Hunter